Improving Oesophageal Adenocarcinoma Outcomes Through Understanding Genomics And Treatment Toxicity.
Funder
National Health and Medical Research Council
Funding Amount
$1,013,282.00
Summary
Oesophageal adenocarcinoma is an aggressive cancer, as most patients will not survive for more than 5 years. Therefore we need to find better ways to treat patients. In this study we will identify the DNA mutations in oesophageal cancers that were part of clinical trial. The data allow us to determine why some tumours responded well to therapy, and why some patients had serious side effects to the treatment. The results will help inform on selection of therapy for future patients.